InvestSMART

Oncosil Medical Limited (ASX: OSL) - Announcements

- Current share price for OSL : $0.675

ASX company news and announcements for Oncosil Medical Limited (OSL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Oncosil Medical Limited (OSL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Oncosil Medical Limited (OSL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Oncosil Medical Limited (OSL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$21 Proposed issue of securities - OSL 3 Feb 2026 10:53AM $0.800 $0.675 fallen by 15.63%
$21 Prospectus 3 Feb 2026 10:52AM $0.800 $0.675 fallen by 15.63%
$21 $8.0 million Capital Raise for Ongoing Commercial Expansion 3 Feb 2026 10:52AM $0.800 $0.675 fallen by 15.63%
$21 OncoSil delivers strong early clinical results in Turkiye 30 Jan 2026 10:32AM $0.800 $0.675 fallen by 15.63%
$21 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2026 9:32AM $0.800 $0.675 fallen by 15.63%
$21 Trading Halt 30 Jan 2026 9:06AM $0.800 $0.675 fallen by 15.63%
$21 TRIPP-FFX Trial Completes Last Patient Last Visit 28 Jan 2026 9:32AM $0.840 $0.675 fallen by 19.64%
$21 First Patient Treatment at Vivantes Neukolln Hospital 27 Jan 2026 9:45AM $0.760 $0.675 fallen by 11.18%
$21 First Treatment at Acibadem Maslak Hospital in Turkiye 15 Jan 2026 11:00AM $0.920 $0.675 fallen by 26.63%
$21 New Scientific Paper Highlights Benefits of OncoSil Device 12 Jan 2026 10:07AM $0.870 $0.675 fallen by 22.41%
$21 OncoSil receives $1.84m R&D tax incentive 7 Jan 2026 1:02PM $0.840 $0.675 fallen by 19.64%
$21 Notification of cessation of securities - OSL 7 Jan 2026 8:33AM $0.900 $0.675 fallen by 25%
$21 Successful OncoSil Device Production at New Sydney Facility 17 Dec 2025 10:08AM $1.090 $0.675 fallen by 38.07%
$21 Notification of cessation of securities - OSL 11 Dec 2025 8:23AM $1.010 $0.675 fallen by 33.17%
$21 First OncoSil treatment in United Kingdom 10 Dec 2025 9:50AM $1.025 $0.675 fallen by 34.15%
$21 OSPREY Analysis Shows Survival Benefit for OncoSil Patients 3 Dec 2025 9:33AM $1.135 $0.675 fallen by 40.53%
$21 Change of Director's Interest Notice x3 2 Dec 2025 9:02AM $1.113 $0.675 fallen by 39.33%
$21 Notification regarding unquoted securities - OSL 1 Dec 2025 3:33PM $1.113 $0.675 fallen by 39.33%
$21 Application for quotation of securities - OSL 1 Dec 2025 3:20PM $1.113 $0.675 fallen by 39.33%
$21 Final Director's Interest Notice 21 Nov 2025 10:53AM $1.280 $0.675 fallen by 47.27%
$21 Notification of cessation of securities - OSL 21 Nov 2025 10:51AM $1.280 $0.675 fallen by 47.27%
$21 Investor presentation - Bell Potter Healthcare Conference 20 Nov 2025 11:18AM $1.085 $0.675 fallen by 37.79%
$21 Results of Meeting 19 Nov 2025 2:11PM $1.200 $0.675 fallen by 43.75%
$21 AGM Chairman's Address and CEO & MD Presentation 19 Nov 2025 10:51AM $1.200 $0.675 fallen by 43.75%
$21 Retirement of Non-Executive Director 3 Nov 2025 9:23AM $1.255 $0.675 fallen by 46.22%

51 - 75 of 779 results

Page 3 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.